The Motley Fool Previous Page

"Better Than Nothing" Doesn't Cut It for Zalicus

Brian Orelli, Ph.D.
September 10, 2012

First, the good news: In a phase 2b trial, Zalicus' (Nasdaq: ZLCS  ) Synavive passed its primary endpoint, improving patients' rheumatoid arthritis symptoms compared with placebo.

Despite the seemingly good news, Zalicus has decided to stop development of the drug.

For indications with high unmet need, beating placebo is usually good enough. But for diseases such as rheumatoid arthritis, being better than placebo just doesn't cut it. There are too many other options for patients.

In addition to being compared to placebo, Synavive was compared to its individual components -- prednisolone and dipy